Myeloid neoplasm-related gene abnormalities differentially affect dendritic cell differentiation from murine hematopoietic stem/progenitor cells

Immunology Letters

Volumn 136, Issue 1, 2011, Pages 61-73

  Fujita, Jiro ^a   Mizuki, Masao ^a   Otsuka, Masayasu ^a   Ezoe, Sachiko ^a   Tanaka, Hirokazu ^a   Satoh, Yusuke ^a   Fukushima, Kentaro ^a   Tokunaga, Masahiro ^a   Matsumura, Itaru ^a   Kanakura, Yuzuru ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

DC culture; Leukemia; Myelodysplastic syndrome; Transcription factor; Tumor immunology; Tyrosine kinase

Indexed keywords

FLT3 LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MIXED LINEAGE LEUKEMIA PROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN TYROSINE KINASE; RAS PROTEIN; STAT5 PROTEIN; STEM CELL ANTIGEN 1; STEM CELL FACTOR;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL LINEAGE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; GENE TARGETING; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; TUMOR IMMUNOLOGY;

ANIMALS; ANTIGENS, LY; CELL DIFFERENTIATION; CELL LINEAGE; CELLS, CULTURED; COCULTURE TECHNIQUES; DENDRITIC CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; MAP KINASE KINASE 1; MEMBRANE PROTEINS; MICE; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-KIT; STAT5 TRANSCRIPTION FACTOR;

EID: 79952316287     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.12.006     Document Type: Article

References (74)

1. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
2. Steinman R.M., Hawiger D., Liu K., Bonifaz L., Bonnyay D., Mahnke K., et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci 2003, 987:15-25.
3. Shortman K., Naik S.H. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 2007, 7:19-30.
4. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
5. Dhodapkar M.V., Dhodapkar K.M., Palucka A.K. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ 2008, 15:39-50.
6. Melief C.J. Cancer immunotherapy by dendritic cells. Immunity 2008, 29:372-383.
7. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004, 4:941-952.
8. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001, 194:769-779.
9. Sharma M.D., Baban B., Chandler P., Hou D.Y., Singh N., Yagita H., et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007, 117:2570-2582.
10. Curiel T.J., Wei S., Dong H., Alvarez X., Cheng P., Mottram P., et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003, 9:562-567.
11. Houtenbos I., Westers T.M., Ossenkoppele G.J., van de Loosdrecht A.A. Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia. Immunobiology 2006, 211:677-685.
12. Li L., Reinhardt P., Schmitt A., Barth T.F., Greiner J., Ringhoffer M., et al. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol Immunother 2005, 54:685-693.
13. Mohty M., Jarrossay D., Lafage-Pochitaloff M., Zandotti C., Briere F., de Lamballeri X.N., et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood 2001, 98:3750-3756.
14. Fujii S., Shimizu K., Koji F., Kawano F. Malignant counterpart of myeloid dendritic cell (DC) belonging to acute myelogenous leukemia (AML) exhibits a dichotomous immunoregulatory potential. J Leukoc Biol 2003, 73:82-90.
15. Orsini E., Calabrese E., Maggio R., Pasquale A., Nanni M., Trasarti S., et al. Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation. Leuk Res 2006, 30:785-794.
16. Ma L., Delforge M., van Duppen V., Verhoef G., Emanuel B., Boogaerts M., et al. Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes. Leukemia 2004, 18:1451-1456.
17. Micheva I., Thanopoulou E., Michalopoulou S., Kakagianni T., Kouraklis-Symeonidis A., Symeonidis A., et al. Impaired generation of bone marrow CD34-derived dendritic cells with low peripheral blood subsets in patients with myelodysplastic syndrome. Br J Haematol 2004, 126:806-814.
18. Schmitt M., Casalegno-Garduno R., Xu X., Schmitt A. Peptide vaccines for patients with acute myeloid leukemia. Expert Rev Vaccines 2009, 8:1415-1425.
19. Xu Y., Zhan Y., Lew A.M., Naik S.H., Kershaw M.H. Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. J Immunol 2007, 179:7577-7584.
20. Naik S.H., Proietto A.I., Wilson N.S., Dakic A., Schnorrer P., Fuchsberger M., et al. Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J Immunol 2005, 174:6592-6597.
21. Spiekermann K., Bagrintseva K., Schwab R., Schmieja K., Hiddemann W. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res 2003, 9:2140-2150.
22. Fenski R., Flesch K., Serve S., Mizuki M., Oelmann E., Kratz-Albers K., et al. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol 2000, 108:322-330.
23. Delgado M.D., Vaque J.P., Arozarena I., Lopez-Ilasaca M.A., Martinez C., Crespo P., et al. H-K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism. Oncogene 2000, 19:783-790.
24. Hashimoto K., Matsumura I., Tsujimura T., Kim D.K., Ogihara H., Ikeda H., et al. Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation. Blood 2003, 101:1094-1102.
25. Stover E.H., Chen J., Lee B.H., Cools J., McDowell E., Adelsperger J., et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 2005, 106:3206-3213.
26. Shimizu K., Kitabayashi I., Kamada N., Abe T., Maseki N., Suzukawa K., et al. AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon. Blood 2000, 96:288-296.
27. Alcalay M., Tomassoni L., Colombo E., Stoldt S., Grignani F., Fagioli M., et al. The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol Cell Biol 1998, 18:1084-1093.
28. Zhao L., Cannons J.L., Anderson S., Kirby M., Xu L., Castilla L.H., et al. CBFB-MYH11 hinders early T-cell development and induces massive cell death in the thymus. Blood 2007, 109:3432-3440.
29. Satoh Y., Matsumura I., Tanaka H., Ezoe S., Fukushima K., Tokunaga M., et al. AML1/RUNX1 works as a negative regulator of c-Mpl in hematopoietic stem cells. J Biol Chem 2008, 283:30045-30056.
30. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., et al. Stat3 as an oncogene. Cell 1999, 98:295-303.
31. Matsumura I., Kitamura T., Wakao H., Tanaka H., Hashimoto K., Albanese C., et al. Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J 1999, 18:1367-1377.
32. Doornbos R.P., Theelen M., van der Hoeven P.C., van Blitterswijk W.J., Verkleij A.J., van Bergen en Henegouwen P.M. Protein kinase Czeta is a negative regulator of protein kinase B activity. J Biol Chem 1999, 274:8589-8596.
33. Satoh Y., Matsumura I., Tanaka H., Ezoe S., Sugahara H., Mizuki M., et al. Roles for c-Myc in self-renewal of hematopoietic stem cells. J Biol Chem 2004, 279:24986-24993.
34. Nakano H., Yanagita M., Gunn M.D. CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med 2001, 194:1171-1178.
35. O'Keeffe M., Hochrein H., Vremec D., Caminschi I., Miller J.L., Anders E.M., et al. Mouse plasmacytoid cells: long-lived cells, heterogeneous in surface phenotype and function, that differentiate into CD8(+) dendritic cells only after microbial stimulus. J Exp Med 2002, 196:1307-1319.
36. Nikolic T., Dingjan G.M., Leenen P.J., Hendriks R.W. A subfraction of B220(+) cells in murine bone marrow and spleen does not belong to the B cell lineage but has dendritic cell characteristics. Eur J Immunol 2002, 32:686-692.
37. Pelayo R., Hirose J., Huang J., Garrett K.P., Delogu A., Busslinger M., et al. Derivation of 2 categories of plasmacytoid dendritic cells in murine bone marrow. Blood 2005, 105:4407-4415.
38. Blasius A.L., Barchet W., Cella M., Colonna M. Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells. J Exp Med 2007, 204:2561-2568.
39. Brasel K., De Smedt T., Smith J.L., Maliszewski C.R. Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood 2000, 96:3029-3039.
40. Maraskovsky E., Brasel K., Teepe M., Roux E.R., Lyman S.D., Shortman K., et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996, 184:1953-1962.
41. Naik S.H., Sathe P., Park H.Y., Metcalf D., Proietto A.I., Dakic A., et al. Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nat Immunol 2007, 8:1217-1226.
42. Naik S.H. Generation of large numbers of pro-DCs and pre-DCs in vitro. Methods Mol Biol 2010, 595:177-186.
43. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532-1542.
44. Waskow C., Liu K., Darrasse-Jeze G., Guermonprez P., Ginhoux F., Merad M., et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol 2008, 9:676-683.
45. Naik S.H., Metcalf D., van Nieuwenhuijze A., Wicks I., Wu L., O'Keeffe M., et al. Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. Nat Immunol 2006, 7:663-671.
46. Scholl C., Gilliland D.G., Frohling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 2008, 35:336-345.
47. Rutella S., Danese S., Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006, 108:1435-1440.
48. Blank C., Brown I., Peterson A.C., Spiotto M., Iwai Y., Honjo T., et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004, 64:1140-1145.
49. Hirano F., Kaneko K., Tamura H., Dong H., Wang S., Ichikawa M., et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005, 65:1089-1096.
50. Strome S.E., Dong H., Tamura H., Voss S.G., Flies D.B., Tamada K., et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003, 63:6501-6505.
51. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002, 99:12293-12297.
52. Mumprecht S., Schurch C., Schwaller J., Solenthaler M., Ochsenbein A.F. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009, 114:1528-1536.
53. Zhang L., Gajewski T.F., Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009, 114:1545-1552.
54. Liu J., Hamrouni A., Wolowiec D., Coiteux V., Kuliczkowski K., Hetuin D., et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007, 110:296-304.
55. Mohty M., Isnardon D., Vey N., Briere F., Blaise D., Olive D., et al. Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of CD34+/CD38- primitive haematopoietic progenitors. Br J Haematol 2002, 119:115-118.
56. Boissel N., Rousselot P., Raffoux E., Cayuela J.M., Maarek O., Charron D., et al. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia 2004, 18:1656-1661.
57. Floisand Y., Normann A.P., Heim S., Lund-Johansen F., Tjonnfjord G.E. High expression of CD7 on CD34+ cells is not linked to deletion of derivative chromosome 9 or lack of dendritic cells in chronic myeloid leukaemia. Scand J Clin Lab Invest 2008, 68:93-98.
58. Panoskaltsis N. Dendritic cells in MDS and AML-cause, effect or solution to the immune pathogenesis of disease?. Leukemia 2005, 19:354-357.
59. Robinson S.P., Patterson S., English N., Davies D., Knight S.C., Reid C.D. Human peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol 1999, 29:2769-2778.
60. Reading C.L., Estey E.H., Huh Y.O., Claxton D.F., Sanchez G., Terstappen L.W., et al. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 1993, 81:3083-3090.
61. Bahia D.M., Yamamoto M., Chauffaille Mde L., Kimura E.Y., Bordin J.O., Filgueiras M.A., et al. Aberrant phenotypes in acute myeloid leukemia: a high frequency and its clinical significance. Haematologica 2001, 86:801-806.
62. Bhushan B., Chauhan P.S., Saluja S., Verma S., Mishra A.K., Siddiqui S., et al. Aberrant phenotypes in childhood and adult acute leukemia and its association with adverse prognostic factors and clinical outcome. Clin Exp Med 2010, 10:33-40.
63. Zhou G., Drake C.G., Levitsky H.I. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006, 107:628-636.
64. Maksimow M., Miiluniemi M., Marttila-Ichihara F., Jalkanen S., Hanninen A. Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor immunity. Blood 2006, 108:1298-1305.
65. Wei S., Kryczek I., Zou L., Daniel B., Cheng P., Mottram P., et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 2005, 65:5020-5026.
66. Munn D.H., Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007, 117:1147-1154.
67. Schlenk R.F., Dohner K., Krauter J., Frohling S., Corbacioglu A., Bullinger L., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.
68. Yanada M., Matsuo K., Suzuki T., Kiyoi H., Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 2005, 19:1345-1349.
69. Onai N., Manz M.G. The STATs on dendritic cell development. Immunity 2008, 28:490-492.
70. Cohen P.A., Koski G.K., Czerniecki B.J., Bunting K.D., Fu X.Y., Wang Z., et al. STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood 2008, 112:1832-1843.
71. Tao M., Li B., Nayini J., Andrews C.B., Huang R.W., Devemy E., et al. SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients. Cytokine 2000, 12:699-707.
72. Panoskaltsis N., Reid C.D., Knight S.C. Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia. Leukemia 2003, 17:716-730.
73. Mumprecht S., Claus C., Schurch C., Pavelic V., Matter M.S., Ochsenbein A.F. Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells. Blood 2009, 113:4681-4689.
74. Sotomayor E.M., Borrello I., Rattis F.M., Cuenca A.G., Abrams J., Staveley-O'Carroll K., et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 2001, 98:1070-1077.